Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009 (Q57111038)

From Wikidata

Jump to navigation Jump to search

article

Language	Label	Description	Also known as
English	Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009	article

Statements

scholarly article

0 references

Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009 (English)

0 references

1 reference

based on heuristic

inferred from title

World Health Organization

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Marie Paule Kieny

4

object named as

Marie Paule Kieny

0 references

Frederick G Hayden

1

object named as

Frederick G Hayden

0 references

author name string

Wendy A Howard

2

0 references

Laszlo Palkonyay

3

0 references

language of work or name

0 references

publication date

24 June 2009

0 references

0 references

27

0 references

4079-89

0 references

31

0 references

Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Safety, humoral and cell mediated immune responses to two formulations of an inactivated, split-virion influenza A/H5N1 vaccine in children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Cross-neutralisation of antibodies elicited by an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Report of the 4th meeting on the "Evaluation of pandemic influenza prototype vaccines in clinical trials." World Health Organization, Geneva, Switzerland, 14-15 February 2008.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

A commercial ELISA detects high levels of human H5 antibody but cross-reacts with influenza A antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Lack of cross-immune reactivity against influenza H5N1 from seasonal influenza vaccine in humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I-II clinical trials).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

An influenza A vaccine based on tetrameric ectodomain of matrix protein 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Identifiers

10.1016/J.VACCINE.2009.04.059

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57111038&oldid=1953544759"